<DOC>
	<DOCNO>NCT00002268</DOCNO>
	<brief_summary>To determine safety , tolerance , potential vivo antiviral effect five dosage level dose determine human anti-cytomegalovirus ( CMV ) monoclonal antibody ( SDZ MSL-109 ; formerly SDZ 89-109 ) administer every 2 week total 12 dose patient either AIDS eligible AIDS-related complex ( ARC ) culture prove evidence CMV viremia and/or viruria . Sandoglobulin employ comparative control .</brief_summary>
	<brief_title>A Randomized , Phase I/II Trial Assess Safety Antiviral Effects Escalating Doses A Human Anti-Cytomegalovirus Monoclonal Antibody ( SDZ MSL-109 ) Patients With Acquired Immunodeficiency Syndrome CMV Viremia and/or Viruria</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Zidovudine ( AZT ) . Acyclovir . Experimental maintenance prophylactic therapy approve therapeutic agent nonviral opportunistic infection . Trimethoprim / sulfamethoxazole ( TMP / SMX ) . Pyrimethamine / sulfadoxine . Inhaled pentamidine . Amphotericin B. Ketoconazole . Flucytosine ( 5FC ) . Antituberculosis therapy . Recombinant human erythropoietin . Recombinant granulocytemacrophage colonystimulating factor ( GMCSF ) . Recombinant human interferon alfa 2 AIDSrelated Kaposi 's sarcoma . Patients must : AIDS HIV positive CD4 lymphocyte count 200 cells/mm3 receive prophylaxis Pneumocystis carinii pneumonia ( PCP ) ( without prophylaxis another opportunistic infection ) , prior medical history opportunistic infection . Expected survival = &gt; 6 month . Willingness ability give write informed consent . A copy sign witness consent form must maintain investigator 's study file . Positive culture result document presence cytomegalovirus ( CMV ) viremia and/or viruria . Seropositive presence circulate antiCMV immunoglobulin . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Significant pulmonary dysfunction . Uncontrolled unstable diabetes . Significant cardiovascular disease include uncontrolled hypertension , congestive heart failure , cardiac arrhythmia , angina pectoris , history myocardial infarction within one year entry study . Coagulation hemorrhagic disorder . Any active severe opportunistic infection . Concurrent Medication : Excluded : Therapy ganciclovir ( DHPG ) phosphonoformate ( PFA ) experimental anticytomegalovirus therapy except stipulate protocol . Any experimental antiviral therapy . Biologicals include immunoglobulin therapy ( except patient randomize receive Sandoglobulin specify protocol ) . Patients follow exclude : Any significant organ system dysfunction describe Exclusion coexist condition . Previous history evidence idiopathic thrombocytopenia purpura , agammaglobulinemia , hypogammaglobulinemia . Any severe concomitant clinical condition . Documented , active cytomegalovirus ( CMV ) disease ( tissue organ invasion/dysfunction ) baseline . To end , baseline indirect funduscopy ( detect exclude patient peripheral CMV retinitis ) perform . Prior Medication : Excluded within 2 week study entry : Therapy ganciclovir ( DHPG ) phosphonoformate ( PFA ) experimental anticytomegalovirus therapy except stipulate protocol . Any experimental antiviral therapy . Biologicals include immunoglobulin therapy ( except patient randomize receive Sandoglobulin specify protocol ) . Excluded : Prior treatment monoclonal antibody derive animal specie . Prior Treatment : Excluded within 2 week study entry : Major surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1991</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
</DOC>